BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems (DCTH)Delcath Systems2026-06-25 13:46 ESTEarnings

2026 Revenue Guidance of at least $100M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, N.Y. --(BUSINESS WIRE)--May 7, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced

Open original release

Related news

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

View all latest news

Delcath Systems

Delcath Systems is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

DCTHDelcath Systems2026-06-26 06:05 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

DCTHDelcath Systems2026-06-26 06:05 EST

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

DCTHDelcath Systems2026-06-26 06:05 EST

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-06-26 06:05 EST

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

DCTHDelcath Systems2026-06-26 06:05 EST

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States